Fig. 2 | Leukemia

Fig. 2

From: Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

Fig. 2

Mutation profiling of primary AML samples and sensitivity to BCL-2/MCL1 targeting. Sensitivity to combined S55746/S63845 is shown, with sensitive samples (LC50 < 100 nM) colored red and resistant cases (LC50 > 100 nM) green. Prior patient resistance to chemotherapy is indicated by orange colored boxes. Mutation presence is indicated by filled black boxes for each sample. Cytogenetic abnormalities are summarized, with gray shading indicating adverse-risk karyotype. Missing FLT3-ITD values are indicated (NA)

Back to article page